Our Technology

NKGen Biotech’s proprietary autologous and allogeneic cellular immunotherapies achieve high-fold cell expansion of highly activated and pure natural killer (NK) cells.

SuperNK™ (SNK)

NKGen Biotech’s innovative and unique NK cell immunotherapy, SNK, involves the infusion of one’s own activated NK cells into the body with the goal to improve immune system function, eliminate diseased or abnormal cells and prevent recurrence.  SNK uses highly pure NK cells harvested from the patient’s blood, activated and infused back into the patient’s body.

SNK stands out from other available therapies because it is autologous, not genetically modified and has less chance of side effects than other therapies such as chimeric antigen receptor T cell (CAR-T) treatments.

SNK has a broad therapeutic potential within the areas of cancer, autoimmune and neurodegenerative diseases.

Autologous NK cell immunotherapy is treatment that provides immune enhancement using highly pure NK cells harvested from a patient’s body.

SNK Technology

Autolgous Manufacturing Slide 8.3.23


NKGen Biotech’s  U.S. headquarters is a state-of-the-art cGMP cell therapy manufacturing facility. At 25,000 square feet, it is home to our growing U.S. team including our CAP/CLIA certified laboratory, enabling us to manufacture clinical and commercial product.

3001 Daimler Street, Santa Ana, California


25,000 sf

(12,000 sf for GMP)

Overall Building Size


of doses/year

Production Capacity

September 2019

Completion of GMP